Stifel Nicolaus Starts Loxo Oncology (LOXO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Cowen Starts Loxo Oncology (LOXO) at Outperform
September 2, 2014 6:54 AM EDTCowen initiated coverage on Loxo Oncology (NASDAQ: LOXO) with an Outperform rating.
For an analyst ratings summary and ratings history on Loxo Oncology click here. For more ratings news on Loxo Oncology click here.
Shares of Loxo Oncology closed at $13.01 yesterday.
... MoreOppenheimer Starts Loxo Oncology (LOXO) at Outperform
September 2, 2014 6:28 AM EDTOppenheimer initiates coverage on Loxo Oncology (NASDAQ: LOXO) with a Outperform rating and a price target of $20.00.
Analyst Yigal Nochomovitz, Ph.D. commented, "Loxo is an early-stage biotechnology company executing a business plan for targeted cancer drugs that benefits from 1) clear precedent for... More
